{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:43Z","timestamp":1791814543725,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ajo.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:54:55Z","timestamp":1729713295000},"page":"172-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-2421","authenticated-orcid":false,"given":"Gabriel T.","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-575X","authenticated-orcid":false,"given":"Nicholas","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakshu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3021-5630","authenticated-orcid":false,"given":"Matthew R.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2024.10.017_bib0001","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","article-title":"Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration","volume":"16","author":"Avery","year":"1996","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2024.10.017_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000027400","article-title":"Natural history of macular subretinal hemorrhage in age-related macular degeneration","volume":"213","author":"Scupola","year":"1999","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2024.10.017_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ajo.2016.06.014","article-title":"Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy","volume":"169","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2024.10.017_bib0004","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","article-title":"Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti\u2013vascular endothelial growth factor injections","volume":"40","author":"Starr","year":"2020","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2024.10.017_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3928\/23258160-20210302-02","article-title":"Characterizing progression to neovascular AMD in fellow eyes of patients treated with intravitreal anti-VEGF injections","volume":"52","author":"Starr","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"10.1016\/j.ajo.2024.10.017_bib0006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.oret.2020.07.028","article-title":"The timing of large submacular hemorrhage secondary to age-related macular degeneration relative to anti\u2013VEGF therapy","volume":"5","author":"Matsunaga","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"10.1016\/j.ajo.2024.10.017_bib0007","doi-asserted-by":"crossref","first-page":"e1569","DOI":"10.1111\/aos.15137","article-title":"Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry","volume":"100","author":"Gabrielle","year":"2022","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"10","key":"10.1016\/j.ajo.2024.10.017_bib0008","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/IAE.0b013e3181e2263c","article-title":"Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration","volume":"30","author":"Fine","year":"2010","journal-title":"Retina Phila Pa"},{"issue":"4","key":"10.1016\/j.ajo.2024.10.017_bib0009","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/IAE.0b013e318233abb4","article-title":"Recurrent submacular hemorrhage in patients with neovascular age-related macular degeneration","volume":"32","author":"Hwang","year":"2012","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajo.2024.10.017_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3341\/kjo.2015.29.5.315","article-title":"Clinical outcomes of eyes with submacular hemorrhage secondary to age-related macular degeneration treated with anti-vascular endothelial growth factor","volume":"29","author":"Kim","year":"2015","journal-title":"Korean J Ophthalmol KJO"},{"issue":"9","key":"10.1016\/j.ajo.2024.10.017_bib0011","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ophtha.2023.04.014","article-title":"Surgery, tissue plasminogen activator, antiangiogenic agents, and age-related macular degeneration study: a randomized controlled trial for submacular hemorrhage secondary to age-related macular degeneration","volume":"130","author":"Gabrielle","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.10.017_bib0012","first-page":"292","article-title":"Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in na\u00efve submacular haemorrhage secondary to nAMD. \u201cThe Submarine Study\u201d","volume":"38","author":"Iglicki","year":"2024","journal-title":"Eye Lond Engl"},{"issue":"6","key":"10.1016\/j.ajo.2024.10.017_bib0013","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2024.10.017_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2024.10.017_bib0015","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2024.10.017_bib0016","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","article-title":"A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact","volume":"117","author":"Gupta","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2024.10.017_bib0017","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","article-title":"Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy","volume":"30","author":"Engelbert","year":"2010","journal-title":"Retina Phila Pa"},{"issue":"8","key":"10.1016\/j.ajo.2024.10.017_bib0018","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/IAE.0b013e3181b09443","article-title":"Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy","volume":"29","author":"Levine","year":"2009","journal-title":"Retina Phila Pa"},{"key":"10.1016\/j.ajo.2024.10.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/ICB.0000000000001542","article-title":"Intravitreal faricimab as an adjuvant in the management of tubercular uveitis","author":"Alcibahy","year":"2023","journal-title":"Retin Cases Brief Rep"},{"issue":"50","key":"10.1016\/j.ajo.2024.10.017_bib0020","doi-asserted-by":"crossref","first-page":"e36370","DOI":"10.1097\/MD.0000000000036370","article-title":"Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ajo.2024.10.017_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424004860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424004860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:09:44Z","timestamp":1737500984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424004860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":21,"alternative-id":["S0002939424004860"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.10.017","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}